A new study appearing in the July 9 issue of Blood discussed a potential therapeutic treatment that focuses on osteoblasts, the cells responsible for bone formation.

Myeloma patients commonly have high serum DKK1 levels, which may decrease with response to therapy for myeloma. DKK1, an important regulator of bone formation, has previously been associated with bone disease in cancers of the esophagus, lungs, prostate, and colon. However, DKK1 has recently emerged as a therapeutic target for suppressed bone formation. The study analyzed the effect of an antibody that neutralizes DKK1,…

A recent study, presented at the International Academy of Oral Oncology, suggests that in order to prevent jawbone disease, myeloma patients should receive a dental examination before beginning bisphosphonate (BP) therapy.

The duration of BP therapy and the severity of myeloma are linked to the development of jaw bone disease, or osteonecrosis of the jaw (ONJ). ONJ occurs when there is a loss of blood supply to the jaw, causing the jawbone tissue to die.

BPs are a class of drugs that prevent bone from breaking down. They are commonly…

Bone fractures and bone disease are two severe complications affecting myeloma patients. However, treatments such as radiation therapy, vertebroplasty, and kyphoplasty are all used to help myeloma patients combat weakening bone formation.

The most common type of lesions that develop in myeloma patients are in the spinal column. Patients may mistake pain from the lesion, often in the lower back and ribs, to be general back pain. One possible cause for the pain is vertebral compression fractures, also known as spinal fractures. This happens because the bone in the spine is too…

The majority of myeloma patients develop bone disease, which is caused by two main factors: stimulation of cells that break down bone and suppression of cells that make bone. Drugs that alter these processes have therapeutic potential for bone disease.

A biological pathway called RANKL is known to increase break down of bone. Scientists have developed an antibody called denosumab, which decreases bone destruction by blocking the RANKL pathway. One dose of denosumab reduces bone resorption for 90 days. Denosumab is currently in clinical trials; however,…

Most myeloma patients suffer from bone disease, which can cause pain and fractures. Pain caused by bone disease is often treated with localized radiation therapy, and fractures can be stabilized by surgical procedures. However, these therapies only treat symptoms and do not actually slow or prevent further bone disease. Only bisphosphonates (BPs) are commonly used to prevent bone disease associated with myeloma.

BPs are a class of drugs that prevent bone from breaking down. This therapy can decrease bone pain and prevent the development of fractures, but it does not…